Community/Retail

This FAQ describes what oncology pharmacists should know ahead of Gynecologic Cancer Awareness Month in September.

Pharmacists’ medication expertise can mitigate GI adverse effects and improve outcomes for patients beginning obesity pharmacotherapy

A Medicare GLP-1 bridge program marks 2026, while multiagonists like CagriSema are poised to lead the next wave of obesity therapy.

From statins after 70 to aspirin-free STEMI care, the pharmacist takeaway across 13 trials: identify disease earlier, treat precisely, deliver reliably.

The approval makes ustekinumab the first non-TNF-alpha monoclonal antibody available for both major forms of pediatric inflammatory bowel disease (IBD).

From enlicitide to Lp(a)-lowering siRNAs, a look at the add-on therapies helping high-risk patients reach stricter LDL targets below 55 mg/dL.

Pharmacist Jennifer Goldman on why expectation-setting, GI counseling, and nutrition drive glucagon GLP-1 persistence and long-term success.

IPD survivors face years of sharply elevated recurrence risk, yet vaccination remains low.

Craig Beavers, PharmD, breaks down CARDIO-TTRansform, SINGLE-AF, and POET II—and what each means for anticoagulation, stewardship, and monitoring.

Bictegravir/lenacapavir (Bixlenvo) offers the first single-tablet option for many patients with HIV currently receiving complex antiretroviral regimens.

Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.

If Heidi Overton is confirmed, the FDA nominee's views on abortion pills, vaccines, and drug review could reshape pharmacists' daily work.

Andrew Bzowyckyj, PharmD, explains how pharmacists can use albuminuria, ejection fraction, and inflammation to drive earlier CKM risk stratification and patient care.

A diabetologist who lives with type 1 diabetes weighs in on real-time ketone monitoring and what it means for at-risk patients.

Investigators say the nanoparticle candidate's speedy manufacturing process and slow-mutating target could reshape how the field responds to emerging flu strains.

Kidney-protective therapy is now layered. How pharmacists screen, stage by KDIGO, stagger ACE/ARB, SGLT2, GLP-1, and finerenone, and cut CV risk.

New data show Opill reaches uninsured, rural, and younger patients—putting pharmacists at the center of daily dosing counseling.

Older triglyceride drugs manage only 10% to 30% reductions; newer injectables go far further, with FCS as their first key role.

Stacey Cutrell, PharmD, BCACP, CDCES, on the PREVENT calculator, screening for secondary causes, intensive BP targets, and fixing stubborn blood pressure.

Abbott's Libre Duo 10 Day tracks both glucose and ketones to flag rising DKA risk in people with diabetes 2 years and older.

Sunburn and tanning signal DNA damage—learn SPF 30+ sunscreen tips, reapplication, and medication photosensitivity for skin cancer prevention.

The first single-biomarker blood test is cleared for both rule-in and rule-out of amyloid pathology in primary and specialty care.

Certifying pharmacy technicians to administer immunizations streamlines workflow, combats vaccine misinformation, and positions pharmacies to fill a coming gap in physician access.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, explains how pharmacists can spot metabolic dysfunction-associated steatotic liver disease (MASLD) risk, weigh GLP-1 and MASH therapies, and pair medication with lifestyle change.

A lesser-known viral protein may drive both the hyperinflammation and vascular damage seen in severe and long COVID-19.

Novo Nordisk's false-advertising case against Eli Lilly turns on GLP-1 dosing—here's the context pharmacists need when patients ask which drug is better.

Night shift and insomnia may triple long-COVID risk; learn how chronic insomnia and long-COVID links affect health workers and prevention.

Before escalating therapy, Stacey M. Cutrell, PharmD, urges pharmacists to rule out pseudo-resistance and nonadherence driving stubborn blood pressure.